December 13, 2023
Via: HitConsultantIcosavax’s lead program, IVX-A12, is a Phase III-ready vaccine candidate targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). These viruses are leading causes of severe respiratory infections and hospitalizations in older adults and individuals with chronic conditions. Icosavax’s […]
July 17, 2024
Copyright © 2024. All rights reserved
